-

Blackstone Announces Matthew Bromberg, Former COO at Zynga, as Senior Advisor

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced the appointment of Matthew Bromberg, former Chief Operating Officer at Zynga, as a Senior Advisor. Bromberg brings over 20 years of experience across the online and mobile gaming industry, and will advise across Blackstone’s businesses, with a focus on Blackstone Growth (BXG).

Vishal Amin, a Managing Director at Blackstone Growth, said: “Matt is a talented executive who has been a driving force behind the rapid evolution of online and mobile gaming over the past two decades. His experience helping businesses thrive in this particularly fast-moving sector will be invaluable to our investment teams and portfolio companies.”

Matthew Bromberg added: “As a board member at Bumble, I have seen the tremendous impact that Blackstone can deliver to entrepreneurs and their companies. I look forward to becoming a Senior Advisor to the firm and working with the Blackstone team and portfolio.”

Bromberg served as Chief Operating Officer of Zynga Inc., a leading social media game developer, from 2016 to January 2022. Prior to Zynga, he worked in various senior roles at Electronic Arts Inc., a video game company, including Senior Vice President of Strategy and Operations of the mobile division. Previously, Bromberg founded I’mOK Inc., a location-based communication platform for families, served as President and CEO of Major League Gaming Corp., a professional eSports company, and as CEO of Davidson Media Holdings, LLC, an online gaming investment and consulting partnership. Earlier in his career he held a number of roles at AOL Inc. Bromberg serves on the board of directors of Bumble and previously served of the board of Fitbit, Inc. Mr. Bromberg holds a B.A. in English from Cornell University and a J.D. from Harvard Law School.

About Blackstone

Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $915 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, Twitter, and Instagram.

Contacts

Tom Clements
(646) 482-6088
Thomas.Clements@blackstone.com

Blackstone

NYSE:BX

Release Versions

Contacts

Tom Clements
(646) 482-6088
Thomas.Clements@blackstone.com

More News From Blackstone

Blackstone Energy Transition Partners Announces Agreement to Acquire Majority Stake in Advanced Cooling Technologies

NEW YORK & LANCASTER, Pa.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Advanced Cooling Technologies, Inc. (“ACT”) announced today that funds managed by Blackstone Energy Transition Partners (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in ACT, a leading U.S. manufacturer of highly-engineered thermal management and energy efficiency solutions. ACT's executive team will remain in place and continue as significant shareholders in the business. Founded in 2003...

Blackstone Energy Transition Partners Announces Completion of 694MW Magnolia Power Generating Station in Louisiana

NEW YORK & PLAQUEMINE, La.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that private equity funds managed by Blackstone Energy Transition Partners (“Blackstone”) have completed construction of the Magnolia Power Generating Station (“Magnolia Power”), a 694-megawatt greenfield combined cycle gas turbine (“CCGT”) power plant in Plaquemine, Louisiana. Today’s announcement marks the beginning of commercial operations at the plant. Blackstone, through its North American power platform, Ki...

Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance...
Back to Newsroom